Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors

Study summary

1. To determine the outcome of patients with potentially resectable superior sulcus tumors of non-small cell histology treated by surgery followed by accelerated radiation therapy and chemotherapy. 2. To evaluate toxicity, the initial local-regional control rate, sites of and time to local and distant failures.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedSurgery and Chest Irradiation

Plus 3 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 30, 2016 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?M.D. Anderson Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: M.D. Anderson Cancer Center
Interventions being studied: Procedure: Surgery; Radiation: Chest Irradiation; Drug: Cisplatin; Drug: Etoposide; Radiation: Prophylactic Cranial Irradiation

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Early-stage or resectable→

Treatment approach

Chemotherapy→Radiation therapy→Surgery→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. No previous treatment. 2. Tumor must be resectable. 3. \>/= 18 and \</= 70 years of age. 4. Zubrod performance status \</= or higher performance status if based only on pain. 5. Must have adequate bone marrow, liver and renal function as defined in 3.6.

Reasons someone may not be able to joinExclusion criteria

1. Cytological or histological proof of N3 disease. 2. Evidence of metastatic disease to distant sites. 3. Patients with impending cord compression will be ineligible.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of Texas MD Anderson Cancer CenterHouston, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 30, 2016. Always confirm current availability with the study team.

View original record ↗